Actively Recruiting
EACH-ADHF: Early Comprehensive Rehabilitation in Patients With ADHF
Led by Guangdong Provincial People's Hospital · Updated on 2025-08-17
140
Participants Needed
1
Research Sites
186 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
EACH-ADHF: Early Comprehensive Rehabilitation in patients with ADHF study is a multi-center, parallel-group, randomized controlled trial designed to evaluate the effects of the early comprehensive rehabilitation including exercise and inspiratory muscle training, over a period of 6 weeks, on the quality of life of patients with ADHF.
CONDITIONS
Official Title
EACH-ADHF: Early Comprehensive Rehabilitation in Patients With ADHF
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 80 years
- At least one symptom of heart failure upon admission such as dyspnea at rest or with exertion, orthopnea, paroxysmal nocturnal dyspnea, or exertional fatigue
- At least two signs of heart failure including distended jugular veins, enlarged cardiac silhouette, apex beat displacement, third heart sound, increased jugular venous pressure/central venous pressure/pulmonary capillary wedge pressure, pulmonary edema or congestion, peripheral edema, or elevated B-type natriuretic peptide (>100 pg/ml) or NT-proBNP (>300 pg/ml)
- Able to independently perform basic activities of daily living before admission
- Able to complete baseline assessment and start the specified treatment
- Able to walk 4 meters at enrollment (assistive devices allowed)
- Agree to participate, sign informed consent, and cooperate with follow-up
You will not qualify if you...
- Acute heart failure caused by acute myocardial infarction
- Severe aortic valve stenosis
- Hemodynamic instability due to poorly controlled arrhythmias
- Severe heart failure with high-degree atrioventricular block or inadequate heart rate response to pacing during exercise
- Isolated pulmonary hypertension
- Poorly controlled symptomatic orthostatic hypotension
- Hypertrophic obstructive cardiomyopathy
- Stage 5 chronic kidney failure (glomerular filtration rate <15 ml/(min·1.73m²)) or requiring dialysis
- Elevated alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels ≥5 times the upper normal limit
- Awaiting heart transplant or ventricular assist device implantation within six months, or having had a heart transplant
- History of chronic lung disease except COPD, previous lung surgery, or diseases affecting lung function such as scoliosis
- Late-stage diseases other than heart failure
- Medical history affecting protocol compliance such as severe mental disorders, cognitive impairment, substance abuse, or addiction
- Severe language, psychological, or physical disabilities preventing participation
- Pregnant or lactating women or those unwilling/unable to use effective contraception
- Participation in other interventional clinical trials
- Deemed unfit for study participation by researchers
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China, 510080
Actively Recruiting
Research Team
H
Huan Ma, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here